Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| DTS INC | DTSI | 6.89% |
| ANIKA THERAP | ANIK | 6.04% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
We have reiterated our Neutral recommendation on IntercontinentalExchange Inc. (ICE - Analyst Report) based on strong fundamentals, which are partially offset by the expected negative impact of regulations and uncertain industry trends.
The company’s second quarter operating earnings of $1.69 per share were substantially ahead of the Zacks Consensus Estimate of $1.60 and $1.51 reported in the year-ago period.
IntercontinentalExchange’s competitive strength lies in its diverse array of products and broad range of risk management services including trade execution, market data, pre- and post-trade processing and clearing services on an integrated platform.
The company has demonstrated immense growth potential in its futures and OTC markets, thereby gaining a competitive leverage. Over the past several quarters, the company has launched multiple new coal, natural gas and gas oil futures contracts, in order to extensively penetrate the rapidly expanding energy sphere.
IntercontinentalExchange’s organic growth is also significantly driven by strong growth in contract volumes, average daily commission and transaction fees, among others. Despite the global downturn, the company’s markets have shown resilience due to the consistent client demand for its products and risk management services.
Further, IntercontinentalExchange has a sturdy balance sheet with strong cash, receivables and capital position. While treasury cash exceeds the total debt position, total interest coverage also remains healthy, reflecting minimal capital expending and solid operating cash flow growth. These factors also pave the way for efficient capital deployment, primarily through share repurchases.
However, IntercontinentalExchange’s credit business that required heavy investment for start-up initiatives has significantly weakened from the historical highs due to the ongoing sluggish markets that reduced liquidity.
Also, trading participation in certain markets has become limited based on extraordinary volatility coupled with a sustained period of uncertainty relating to creditworthiness of the counter-parties and inadequate availability of credit. These adverse conditions have resulted in credit-freeze, outflows of client funds and investments, reduced market liquidity losses due to declining asset values and loan defaults.
Additionally, IntercontinentalExchange’s operating performance has been modestly hampered by the financial downturn in 2008 and the company’s expenses have also been increasing, thereby reducing the operating and competitive leverage.
Moreover, IntercontinentalExchange is liable to be marred by new laws that impact its market operations. In July 2010, the U.S. Commodity Futures Trading Commission (CFTC) determined that certain contracts traded on IntercontinentalExchange perform significant price discovery functions and, therefore, must be traded in compliance with the statutory provisions applicable to significant price discovery contracts.
With respect to this, in July 2011, the company had to lower its adjusted net capital requirements from CDS clearing members, thereby receiving a shot in the arm.
Later, in October 2011, CFTC further proposed that swaps clearing houses will be required to open access to companies with at least $50 million in capital to allow more participants and manage defaults. IntercontinentalExchange could incur additional costs for infrastructural modifications required for the same.
As a result, the Zacks Consensus Estimate for IntercontinentalExchange’s third quarter earnings currently stands at $1.77 per share, up about 25% year-over-year. Of the 16 firms covering the stock, 14 revised their estimates upward, while no downward revisions were witnessed in the last 30 days.
For 2011, earnings are expected to be about $6.85 per share, up 21% year-over-year.
IntercontinentalExchange competes with CME Group Inc. (CME - Analyst Report) and NASDAQ OMX Group Inc. (NDAQ - Analyst Report). The company currently caries a Zacks #2 Rank, implying a short term Buy rating.
Get the full Analyst Report on ICE - FREE
Get the full Analyst Report on CME - FREE
Get the full Analyst Report on NDAQ - FREE